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Virus-specific CD4+ T cells contribute to effective virus control through a multiplicity of mechanisms including direct effector functions as
well as “help” for B cell and CD8+ T cell responses. Here, we have used the lymphocytic choriomeningitis virus (LCMV) system to assess the
minimal constraints of a dominant antiviral CD4+ T cell response. We report that the core epitope derived from the LCMV glycoprotein (GP) is
11 amino acids in length and provides optimal recognition by epitope-specific CD4+ T cells. Surprisingly, this epitope is also recognized by
LCMV-specific CD8+ T cells and thus constitutes a unique viral determinant with dual MHC class I- and II-restriction.
© 2006 Elsevier Inc. All rights reserved.Keywords: Virus; LCMV; T cell response; CD4; CD8; MHC class I; MHC class IIIntroduction
Effective control of microbial infections, in particular
viruses, relies on the concerted activity of pathogen-specific T
and B cells. While the relative contribution of individual
immune cell subsets depends on the precise determinants of
host-pathogen interaction (nature of the pathogen, route of
pathogen entry, pathogen dosage and host immune status),
CD8+ T cells and B cells constitute the main effector cell
populations in most viral infections (Burton, 2002; Whitton and
Oldstone, 2001; Zinkernagel, 2002). In contrast, antiviral CD4+
T cell responses are for the most part significantly smaller than
CD8+ T cell responses and may wane over time (Seder and
Ahmed, 2003; Sprent and Surh, 2002). Nevertheless, CD4+ T
cells play a critical and multifaceted role at all stages of the⁎ Corresponding authors. M.B.A. Oldstone is to be contacted at Department of
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doi:10.1016/j.virol.2006.12.025adaptive immune response by serving as effectors, helpers and/
or regulators/supressors.
Direct antiviral effector functions elaborated in vivo by
specific CD4+ T cells include the production of cytokines and
chemokines and possibly cytotoxic T cell activity (Appay, 2004;
Jenkins et al., 2001; Seder and Paul, 1994). The traditional
designation of CD4+ T cells as “helper T cells” is based on their
importance for enhancement and modulation of specific
antibody responses (McHeyzer-Williams et al., 2003), but
work over the past few years has made increasingly clear that
additional help is also provided to CD8+ T cell responses
(reviewed, Bevan, 2004). Here, the relevant molecular interac-
tions remain to be elucidated in detail but it appears that,
depending on the in vivo model system under study, induction
of primary CD8+ T cell responses, generation and maintenance
of CD8+ T cell memory as well as secondary CD8+ T cell
immunity are all improved by the activity of specific CD4+ T
cells (Bevan, 2004; Homann, 2002). The complex function of
antiviral CD4+ T cell immunity is further supported by studies
on relevant human diseases such as HIV, EBV, CMV, HBVand
HCV infections (Norris and Rosenberg, 2002). Altogether, it
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CD4+ T cell responses increases with the extent of viral disease
(viral load and associated inflammatory alterations) (Homann,
2002). Finally, in their incarnation as “regulatory T cells”, CD4+
T cells are actively engaged in curtailing immune responses
which may have beneficial (limitation of immunopathology) or
adversarial (incapacitation of CD8+ T cell responses) effects
(Belkaid and Rouse, 2005; Dittmer et al., 2004; Mittrucker and
Kaufmann, 2004).
In the present study, we have employed the lymphocytic
choriomeningitis virus (LCMV) system to further define the
nature of antiviral CD4+ T cell responses (Homann et al., 2001;
Kamperschroer and Quinn, 1999; Lenz et al., 2004; Oxenius
et al., 1995; Varga and Welsh, 1998a, 1998b, 2000; Whitmire
et al., 1998). Originally identified by Oxenius et al. (1995) the
immunodominant population of LCMV-specific CD4+ T cells
in C57Bl/6J mice targets an epitope derived from the viral
glycoprotein (GP61–80) and restricted by I-A
b. Here, we have
used several GP61–80-specific CD4
+ T cell lines and clones, a
battery of truncated peptides from the GP61–80 epitope and
surface plasmon resonance to determine the minimal constraints
and avidities of a dominant, virus-specific T cell receptor
(TCR)–MHC interaction.
Results
Generation of LCMV-specific CD4+ T cell lines and clones
To generate CD4+ T cell lines and clones specific for the
I-Ab-restricted LCMV GP61–80 epitope, a C57Bl6/J mouse was
infected with LCMVArmstrong clone 53b (1.5×105pfu i.p.) to
induce LCMV-specific T cell responses and virus clearance.
Thirteen days later, spleen cells were isolated, depleted of
CD8+ T cells and cultured in the presence of GP61–80 peptide
as detailed in Materials and methods. Forty CD4+ T cell lines
and/or clones were established and tested for TCR usage andFig. 1. Establishment and functional characterization of GP61–80-specific CD4
+ T ce
Materials and methods. To evaluate antigen-specific T cell function and TCR usage,
spleen cells to provide a source for MHC class II-restricted antigen presentation and s
Thy1.1 and TCRVβ8.1/8.2 as well as intracellular IFNγ. Dot plots on the right are g
the left; boxed values indicate percentages of IFNγ+ gated CD4+ T cells.IFNγ production, a hallmark of LCMV-specific CD4+ T cells
(Homann et al., 2001; Kamperschroer and Quinn, 1999; Varga
and Welsh, 1998a; Whitmire et al., 1998). As about 1/3 of
GP61–80-specific effector (data not shown) and memory
(Homann et al., 2001) CD4+ T cells utilize Vβ8.1/8.2 TCRs,
we selected 6 cell lines/clones for further analysis based on
Vβ8.1/8.2 and Vα2 TCR expression as well as efficient IFNγ
induction after resting and restimulation with GP61–80 peptide
(Figs. 1 and 2B).
Differential I-AbGP61–80 binding by CD4
+ T cell lines and
clones
We subsequently evaluated the selected cell lines/clones for
their ability to bind I-AbGP61–80 tetramers. Here, three distinct
staining patterns emerged: (1) efficient tetramer binding (clones
#3 and #31), (2) partial tetramer binding indicative of more than
one TCR specificity present in the cell preparation (cell lines
#21 and #32) and (3) absence of tetramer binding (clones/cell
lines #8 and #35) (Fig. 2A). To evaluate if effective tetramer
staining could be “rescued”, we used a more sensitive staining
technique, tetramers deployed on fluorescent liposomes (Mal-
let-Designé et al., 2003). Although this approach reliably
improved the “signal-to-noise ratio” for clones #3 and #31, it
demonstrated only slight staining above background levels for
clones/cell lines #8, #21 and #35 (Fig. 2A). Furthermore,
tetramer binding did not demonstrate any appreciable correla-
tion with the extent of TCR or CD4 co-receptor expression on
the cell surface as determined by measuring the mean
fluorescent intensity of Vβ8.1/8.2, Vα2 and CD4 staining
(Fig. 2B and data not shown).
Identification of an 11 amino acid core epitope (GP67–77)
In spite of their differential ability to bind MHC class II
tetramers, the prompt induction of IFNγ production in thell lines and clones. CD4+ T cell lines and clones were generated as detailed in
cells were rested by antigen withdrawal, supplemented with congenic (Thy1.1+)
timulated for 5 h with GP61–80 peptide. Cells were subsequently stained for CD4,
ated on Thy1.1-negative CD4+ T cells as indicated by the exemplary dot plot on
Fig. 2. T cell receptor usage by GP61–80-specific CD4
+ T cell clones/lines. (A) CD4+ T cell clones/lines were rested in the absence of antigen and stained for CD4 as
well as tetramers (left column) or tetramer-liposomes (right column) as detailed in Materials and methods. Black tracings indicate staining with I-AbGP61–80 tetramers
or tetramer-liposomes; gray histograms indicate control stains with I-AbOVA323–339 tetramers or tetramer-liposomes. (B) In parallel stains, TCR expression levels were
determined by staining for TCR Vα2 (black tracing); for control stains (gray histograms) cells were stained for TCR Vα8. Values represent the geometric mean of
fluorescence intensity (GMFI) of Vα2 stains.
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this functional assay suitable to determine the minimal
constraints of I-Ab-restricted GP61–80 epitope presentation
and TCR reactivity. Using a panel of truncated peptides and
comparing the extent of IFNγ induction to that elicited by the
native GP61–80 peptide, we identified a core motif of 11
amino acids (GP67–77) that on average induces 2/3 of the
maximal IFNγ response in the 6 cell lines/clones (Fig. 3A).
When tested on primary LCMV-specific CD4+ T cells (8 days
after LCMV infection), the GP67–77-specific response was
consistently of slightly greater magnitude as compared to
GP61–80- or GP64–80-specific responses (Fig. 3B). These
results indicate that flanking residues of the core epitope
present in the GP61–80 and GP64–80 peptides may preclude
recognition of the epitope by a subset of virus-specific CD4+
T cells and identify GP67–77 as the immunodominant LCMV-
specific, I-Ab-restricted CD4+ T cell core epitope.Restriction of the core epitope GP67–77 by both I-A
b and Db
During our analyses of peptide-induced IFNγ production by
primary murine effector CD4+ T cells (Fig. 3A), we noted
unusually high “background staining” in CD4-negative cells
obtained from cultures stimulated with GP67 but not GP64 or
NP309 peptides (Fig. 4A). We therefore evaluated the possibility
that the GP67–77 epitope may also be recognized in an MHC-I-
restricted fashion by LCMV-specific CD8+ T cells. In B6 mice,
the majority of specific CD8+ T cells recognize two co-
dominant epitopes restricted by Db (GP33–41 and NP396–404) as
well as two subdominant epitopes restricted by Db and Kb,
respectively (GP276–286 and GP34–43) (Gairin et al., 1995;
Hudrisier et al., 1997; Klavinskis et al., 1990; Oldstone et al.,
1988; Schulz et al., 1989). More recently, several additional
subdominant epitopes have been identified and include the
epitopes GP92–101 and NP166–175 (D
b-restricted) as well as
Fig. 3. Identification of the minimal GP61–80 binding constraints. (A) CD4
+ T
cell clones and lines #3, #8, #21, #31, #32 and #35 were rested by antigen
withdrawal, restimulated with indicated peptides and stained for intracellular
IFNγ. The percentage of IFNγ+ cells after stimulation with the native GP61–80
peptide of individual cell lines or clones was set at 100% and the values after
stimulation with truncated peptides were calculated accordingly. All clones/cell
lines (#3, #8, #21, #31, #32 and #35) were tested in parallel. Data for individual
clones/cell lines obtained in two separate experiments were combined according
to peptide sequences used for stimulation; no statistical analysis was performed
as each value consists of only 2 data points. (B) Eight days after LCMVinfection
of B6 mice, spleen cells were restimulated with indicated peptides and
frequencies of epitope-specific CD4+ T cells were determined by intracellular
IFNγ staining (3 mice/experiment; values indicate SEM of one out of four
independent experiments).
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b-restricted) (van der Most et al.,
2003; van der Most et al., 1998). Indeed, we found that the
GP67–77 epitope is recognized by both LCMV-specific CD4
+
and CD8+ T cells (Fig. 4B) and that Db is the restriction element
for specific CD8+ T cell responses (Fig. 4C) Thus, the GP67–77
epitope constitutes a rather unique viral determinant as it is
targeted, by virtue of its dual restriction, by both CD4+ and
CD8+ T cell populations. Furthermore, since stimulation with
the GP64–80 peptide was not associated with IFNγ induction in
CD8+ Tcells unless provided at excessively high concentrations
(50 μg/ml, data not shown), the presence of the 3 additional
carboxy-terminal (GP64–66) and amino-terminal(GP78–80)
residues apparently interferes with effective Db-restricted
presentation.
Finally, the distribution of GP67–77-specific T cells among
CD4+ and CD8+ T cell subsets was found to be about similar
with 45–50% of GP67–77-reactive T cells expressing either CD4
or CD8 and a minority of T cells specific for this epitope
(<10%) expressing both co-receptors (Fig. 4D).TCR Vβ usage and functional avidities of primary I-Ab and
Db-restricted GP67–77-specific T cells
To assess the distribution of TCR usage by GP67–77-
restricted CD4+ and CD8+ T cells, we utilized a panel of TCR
Vβ-specific antibodies in conjunction with intracellular IFNγ
staining. GP67–77-specific CD4
+ T cells were preferentially
recruited from just two TCR Vβ families (8.1/8.2 and 14)
with several other TCR Vβ families contributing less than 5%
each to the overall GP67–77-restricted CD4
+ T cell response.
In contrast, GP67–77-specific CD8
+ T cells appeared more
diversified as indicated by five TCR Vβ families (2, 8.1/8.2,
8.3, 9, 10) contributing >5% to the overall specific response
as well as larger error bars in the bar diagram reflective of
differential private TCR Vβ usage among individual mice
(Fig. 5A).
We and others have previously reported that the functional
avidities of LCMV-specific CD4+ T cells (measured by
determining the reciprocal peptide concentration required for
IFNγ induction in half of an epitope-specific T cell
population) are considerably lower than those of LCMV-
specific CD8+ T cells (Homann et al., 2002; 2001; Whitmire
et al., 2006). However, a careful interpretation of such data
has to consider that induction of effector functions in this assay
is dependent on both T cell-intrinsic properties (“functional
avidities”) as well as differential binding affinities of synthetic
peptides to MHC class I or II molecules (“structural
aviditities”). Our observation of virus-specific CD4+ and
CD8+ T cells responses specific for the same peptide epitope
now allows for a more direct comparison of functional avidities
between these cell lineages and indicates comparable func-
tional avidities of GP 67–77-specific CD4
+ and CD8+ T cell
populations (Fig. 5B).
Fitting of the core epitope GP67–77 to I-A
b motifs
Based on the identity of naturally processed I-Ab peptides
and the recently solved of I-Ab crystal structure (Dongre et al.,
2001; Zhu et al., 2003), we proposed a common I-Ab-restricted
peptide-binding motif. When applied to the LCMV-GP
sequences, we found that no optimal alignment could be
detected for the 11-mer GP67–77 peptide or longer variants of the
same peptide (Fig. 6A). Attempts to optimize the two most
likely sequence alignments (K-Y-F-V and Y-V-Q-S for P1-P4-
P6-P9, respectively) by substituting non-optimal residues with
canonical residues at the same position failed to produce better
agonistic peptides (Fig. 6B and LT/MBAO, unpublished). The
absence of an optimum register for the GP peptide suggests that
like in the case of I-Ad and I-Ag7, peptides bound to I-Ab can
adopt different alternate registers of binding (Corper et al.,
2000; Scott et al., 1998). This capacity to use alternate registers
has two practical consequences: (i) lower peptide affinity for the
MHC and (ii) increase the repertoire of peptides from any given
pathogen and therefore increase T cell repertoire against this
pathogen. In the case of LCMV, the usage of this strategy to
increase the efficiency of the anti-viral response appears very
appropriate.
Fig. 4. Recognition of the GP67–77 core epitope by both virus-specific CD4
+ and CD8+ T cells. Spleen cells harvested from B6 mice infected with 1.5×105 pfu LCMV
Armstrong i.p. 8 days earlier were stimulated for 5 h with the indicated peptides (nil: no peptide) and analyzed for induced IFNγ expression (Plots are gated on spleen
cells according to FSC/SSC properties. Values indicate percentages of IFNγ+ cells in indicated rectangular gates; absence of values in some gates refers to background
staining levels of <0.1%). (A) Analysis of specific CD4+ T cell responses demonstrates IFNγ induction in CD4-negative cells only after stimulation with GP67 (red
gate) but not GP61 or NP309 peptides. (B) Parallel analyses of IFNγ production by CD8
+ Tcells revealed induction of IFNγ in CD8-negative cells only after stimulation
with GP67 peptide (red gate). (C) Left panel: Seven days after LCMV infection of B6 (D
b+/+/Kb+/+), B6.Db−/−/Kb+/+ and B6.Db−/−/Kb−/− mice, spleen cell suspensions
were tested for specific epitope-specific CTL activity using virus-infected or peptide-coated target cells in a conventional 5 h ex vivo CTL assay. Specific lysis for
effector:target cell cultures at a ratio of 50:1 is shown; values indicate the percentage (SEM) of 51Cr release from target cells. Note that lack of Db expression abolishes
killing of GP65–77 and GP67–77 coated target cells. Right panel: Eight days after infection of B6.D
b−/−/Kb+/+ and B6.Db+/+/Kb−/− mice, epitope-specific CD8+T cell
responses were quantified by peptide restimulation and intracellular IFNg staining; displayed are the percentages of epitope-specific CD8+Tcells (3 mice/group, SEM).
Note that lack of Db expression abolishes GP67–77-induced IFNg production. The NP396–404-specific IFNg response has been included as a control for a bona fide D
b-
restricted CD8+T cell response. (D) Phenotype of GP67–77-specific T cells. Eight days after LCMV infection of B6 mice, spleen cells were restimulated with GP67–77
peptide and stained for CD8α, CD4 and intracellular IFNγ. The dot plot is gated on IFNγ+ T cells indicating the distribution of GP67–77-specific T cells among CD8
+
and CD4+ subsets. The adjacent bar diagram summarizes these findings (3 mice/experiment; 3 independent experiments).
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Having determined the minimal requirements for GP61–80
epitope binding and recognition, we proceeded to investigate
in more detail the binding affinity of selected CD4+ T cell
clones. To this extent, PCR products from clones #3 and #31
were inserted into the pCR2.1-TOPO cloning vector andsequenced. Both I-Ab tetramer-binding CD4+ T cell clones
exhibited identical CDR3 amino acid sequences although we
noted small differences at the level of nucleotide sequences (not
shown). For direct measurement of TCR binding affinity, we
generated recombinant TCRs from clone #3 and evaluated
binding to I-AbGP61–80 complexes by surface plasmon reso-
nance (SPR) as detailed in Materials and methods (Fig. 7). SPR
Fig. 5. TCRVβ usage and functional avidities of GP67–77-specific CD4
+ and CD8+ effector T cells. (A) Effector spleen cells (8 days after LCMV) were restimulated for
5 h with GP67–77 peptide and stained for surface markers (CD8, CD4, TCRVβ subfamily) and intracellular IFNγ. Bar diagrams display relative distribution of TCRVβ
usage by GP67–77-specific (IFNγ
+) CD4+ (black) and CD8+ (gray) T cells. The dotted line indicates the level of non-specific background staining. Bars indicate mean±
SE from 2 independent experiments using 2–3 mice each. (B) Functional avidities were determined by culture of effector spleen cell suspension with graded dosages of
GP61–80 or GP67–77 peptide and plotting of IFNγ
+ effector T cell frequencies (mean±SE) against the peptide concentration used for restimulation (data from 1 of 3
independent experiments using 2–3 mice each). Values listed below the graphs represent the EC50 for indicated peptide specificities and specific T cells, i.e. the peptide
concentration required to elicit detectable IFNγ induction in half of the GP61–80- (left) and GP67–77-specific (right) CD4
+ or CD8+ T cell populations (mean±SE, 1 of 3
independent experiments). Although EC50 values of GP67–77-specific CD4
+ and CD8+ T cells as well as of GP61–80- and GP67–77-specific CD4
+ T cells were not
significantly different, GP67–77-specific CD8
+ T cells exhibited a lower EC50 when compared to GP61–80-specific CD4
+ T cells (p=0.0085).
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indicating a relatively high binding affinity as compared to other
published CD4+ TCR affinities (Krummel et al., 2000).
Discussion
In this study, we have defined the minimal constraints for the
recognition of a dominant, MHC class II-restricted viral
determinant. Naturally processed peptides selected by MHC
class II molecules demonstrate considerable variability of
length (usually 12–26 amino acids) but tend to cluster into
families that share a 9 amino acid core segment that interacts
with the four major binding pockets of the MHC II molecule(p1, p4, p6 and p9). Flanking residues of natural peptides can
modulate binding affinities and also serve as direct contact
residues for TCR recognition (Suri et al., 2006). A recent study
has discerned 128 naturally processed I-Ab-restricted peptides
that are 11–21 amino acids in length and derived from both
endocytic and cytosolic compartments. Although some studies
have begun to employ similar techniques based on tandem
mass-spectrometry for the identification of microbial determi-
nants that are processed and presented by MHC II-bearing cells
in vivo (Meiring et al., 2005; Ovsyannikova et al., 2003), the
majority of studies performed to date have relied on measuring
the binding affinity of synthetic microbial peptides to
recombinant MHC molecules as well as the induction of
Fig. 6. Fitting of dominant LCMV-GP epitope sequences to I-Ab. P1 to P9 signify I-Ab binding pockets. The interactions of individual amino acids with I-Ab binding
pockets are differentiated according to optimal (green), neutral (yellow) and unfavorable (red) binding properties. (A) Potential alignments and registers for GP61–80,
GP64–77 and GP67–77. The shortening of the original peptide was done first using each alignment. (B) Then, the minimal peptide, GP67–77, was modified in 2 registers
to try to increase affinity and T cell response by introducing optimal anchor residues.
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approach has been guided, in particular for the mapping of
MHC I-restricted epitopes, by the identification of common
binding motifs and is usually less effective for prediction of
MHC II-restricted determinants. Nevertheless, information
about the naturally processed I-Ab-restricted peptide sequences
together with the recently solved crystal structure of I-Ab has
allowed for the development of a simple scoring matrix (Dongre
et al., 2001; Zhu et al., 2003). However, retroactive application
of this scoring matrix to the core and related LCMV-GP
epitopes identified in this study failed to reveal optimal binding
sequences. These observations emphasize that in spite of thecomparatively high binding affinities of the dominant LCMV-
GP epitope (Krummel et al., 2000), any attempts to predict
optimal MHC class II-binding epitope sequences are impaired
by the likely usage of alternating peptide binding registers.
The LCMV GP61–80 epitope was originally identified by
Oxenius et al. (1995) as an immunodominant, I-Ab-restricted
determinant derived from the LCMV WE strain. Although
LCMVArmstrong differs from LCMV WE by a single N→K
substitution in position GP63 of this determinant, subsequent
work by other groups established that the GP61–80 epitope is
also dominant for CD4+ T cell responses directed against
LCMV Armstrong (Homann et al., 2001; Kamperschroer and
Fig. 7. Determining the affinity of TCR #3. Recombinant T cell receptors based on sequences derived from clone #3 were constructed as detailed in Materials and
methods and tested for binding to I-AbGP61–80 complexes by plasmon surface resonance. TCR3: recombinant GP61–80-specific TCR obtained from clone #3; Ctl:
control.
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1998b; Whitmire et al., 1998). Indeed, we and others have
estimated that more than half of the I-Ab-restricted, LCMV
Armstrong-specific CD4+ T cell response is directed against
this epitope (Homann et al., 2001; Kamperschroer and Quinn,
1999). More recently, Oxenius' group has utilized a truncated
GP peptide that lacks the first three C-terminal amino acids
(GP64–80) to effectively stimulate TCR transgenic CD4
+ T
cells originally derived from a clone specific for the GP61–80
epitope (Wolint et al., 2004). This finding is in agreement with
our observation that residues GP61–63 are completely dis-
pensable for recognition by GP61–80 specific CD4
+ T cell
clones and also supported by unpublished findings that the
GP-specific CD4+ T cell response is unaltered after infection
with a variant virus lacking GP residues 59–63 (virus
obtained, cloned and sequenced from persistently LCMV
Armstrong-infected Db−/−×Kb−/− mice).
Interestingly, our analyses of primary LCMV-specific T cell
responses directed against the GP67–77 epitope demonstrated the
presence of CD8+ T cells that recognize this epitope in the
context of Db. Although a previous publication, using an in
vitro peptide binding assay, has described a truncated version of
the GP67–77 epitope (GP70–77) as a peptide with high binding
affinity to Kb in (van der Most et al., 1998), the use of Kb as arestriction element for the shorter GP70–77 epitope has, to the
best of our knowledge, not been validated in ex vivo
experiments. It thus remains possible that the GP67–77 and
GP70–77 epitopes indeed demonstrate restriction by different
MHC molecules (Db vs. Kb, respectively) or that GP70–77,
similar to the GP33–41 epitope, is restricted by both D
b and Kb.
Several features are noteworthy in considering binding of
GP67–77 to H-2D
b, a restriction element that has been
investigated in great detail. The signature motif has an Asn at
P5 and an hydrophobic amino acid at P9 (Meth, Ileu or Leu)
(Falk et al., 1991). In the present case, GP67–77 is missing the P5
anchor andwill have to bind to Db in a non-classical way (Ostrov
et al., 2002). It is likely that Valine77 anchors the C-terminus of
the peptide, whereas the middle part bulges out, like most 11mer
peptides bound to MHC class I do (Apostolopoulos et al., 2002;
Ostrov et al., 2002), and is exposed for T cell recognition. The
recognition of one and the same viral determinant by both CD8+
and CD4+ T cells constitutes a unique feature within the LCMV
system and should be taken into consideration for the
interpretation of differential CD4+ and CD8+ T cell activities
in this model system. For example, CD8+ T cells that recognize
the I-Ab-restricted GP61–80 epitope have been described in CD4-
deficient mice (Pearce et al., 2004; Tyznik et al., 2004).
However, this CD8+ T cell response is restricted by I-Ab and its
121D. Homann et al. / Virology 363 (2007) 113–123existence was attributed to abnormal T cell development in
CD4+ T cell-deficient mice since further experiments indicated
that neither wild-type nor acutely CD4-depleted mice mounted
an MHC II-restricted CD8+ T cell response following infection
with recombinant L. monocytogenes expressing a secreted form
of chicken ovalbumin (Tyznik et al., 2004).
Finally, recognition of the same viral determinant by CD4+
and CD8+ T cells may offer an opportunity to optimize
immunization strategies utilizing small, defined peptide
sequences. As shown by van derMost and colleagues, protection
of mice against chronic infection can be achieved even through
induction of subdominant CD8+ T cell responses (van der Most
et al., 1998) that constitute only a very small fraction of the
antiviral CD8+ Tcell population in a natural infection (∼2%). To
improve the overall effectiveness of these CD8+ T cell
responses, the authors utilized a lipidated LCMV GP92–101
peptide conjugated to an ovalbumin “helper” epitope (van der
Most et al., 1998), a strategy that may be simplified by the use of
the GP67–77 core peptide and the concurrent induction of
genuine virus-specific CD8+ and CD4+ T cell responses.
Materials and methods
Mice and virus
C57BL/6 (H-2b, Thy1.2+) and congenic B6.PL (Thy1.1+)
mice were purchased from the closed vivarium breeding colony
at The Scripps Research Institute. Mice lacking Db, Kb or
Db×Kb expression were obtained from Taconic, Hudson NY.
Origin, growth and titration of lymphocytic choriomeningitis
virus (LCMV) Armstrong clone 53b have been described
(Homann et al., 1998). Eight to ten week old C57BL/6 mice
were infected with a single intraperitoneal dose of 105 plaque
forming units LCMVArmstrong.
CD4+ T cell lines and clones
LCMV GP61–80-specific, I-A
b-restricted CD4+ T cell lines
and clones were obtained from C57BL/6 mice 13 days after
infection with 1.5×105 pfu LCMVArmstrong i.p. Spleens were
harvested, single cell suspensions prepared, red blood cell lysed
and CD8+ Tcells depleted with antibody-coated magnetic beads
as described (Berger et al., 2000). Cell counts were adjusted to
5×106 cells/ml in cloning medium (RPMI 1640 supplemented
with 8% FCS, 1% penicillin/streptomycin, 1 mM L-glutamine
and 50 units of human IL-2) supplemented with 1 μg/ml GP61–80
peptide, and plated in 24-well tissue culture plates. After 1 week,
cultures were supplemented regularly with “feeder cells”
(irradiated C57BL/6 spleen cells) as needed, intermittently
rested by withdrawal of LCMV GP61–80 peptide and specific
CD4+ T cell lines and clones established by limiting dilution
techniques (Anderson et al., 1985).
Flow cytometry
For detection of intracellular IFNγ, rested cell lines and
clones as well as primary T cells were restimulated for 5 h withpeptides (1–5 μg/ml) prior to surface and intracellular stains as
detailed elsewhere (Homann et al., 2001). Preparation and use
of I-Ab tetramers and tetramer-liposomes have been described
(Homann et al., 2001; Mallet-Designé et al., 2003). In this
study, tetramers (20 μg/ml; 40 μl volume) were incubated with
cells at room temperature for 45–75 min prior to addition of
antibody reagents, further incubation (20 min), washes and
immediate acquisition on a BD FACSCalibur flow cytometer.
For quantitation of expression levels, we used the normalized
geometric mean of fluorescence intensity (GMFI, calculated by
dividing GMFI of the experimental stain by GMFI of
corresponding control stain). Functional avidities were deter-
mined as described (Homann et al., 2006; Homann et al., 2002).
For determination of TCR Vβ usage, we employed a kit
comprising a panel of available TCR Vβ-specific antibodies
(BDPharmingen).
CTL assay
Direct ex vivo CTL activity was analyzed 7 days after
LCMV infection in a standard 51Cr release assay as described
(Homann et al., 1998).
Sequencing and recombinant expression of TCRs
The cDNA for the α and β chain of TCR for CD4 T cell
clones #3 and #31 was obtained by RT-PCR using Ready-To-
Go RT-PCR beads (Amersham Pharmacia Biotech, Piscataway,
NJ) according to the manufacturer's instructions. In brief, RNA
isolated from clones was used for cDNA synthesis and PCR
amplification. PCR products were subcloned into pCR2.1-
TOPO cloning vector (Invitrogen, Carlsbad, CA), sequenced
and subcloned into the metallothionein promoter-based fly
expression vector pRMHa3 (Fremont et al., 1992). The final
constructs coded for the α1α2 and β1β2 domains, respectively,
followed by a linker sequence (SSADL), a thrombin site
(LVPRGS), a leucine zipper (acidic for the α chain, basic for the
β chain) (Scott et al., 1996) and a hexahistidine tag. Vectors
were transfected into SC2 cells and stable cell lines and clones
were established. Soluble TCRs were purified from culture
supernatants as described (Garcia et al., 1997; Matsumura et al.,
1992; Scott et al., 1998).
Surface plasmon resonance
A BIACORE 2000 instrument was used to determine
interactions between purified pMHC (peptide:MHC) complexes
and recombinant TCR molecules as described (Mallet-Designé
et al., 2003). In brief, pMHC complexes or TCRs were
immobilized by amine coupling chemistry on a CM5 research
grade sensor chip. Successive injections of pMHC complexes or
TCRs were performed in filtered and degassed PBS buffer at a
flow rate of 20 μl/min at concentrations of 20, 10, 5, 2.5, and
1.25 μM. In all experiments, irrelevant TCR molecules or
irrelevant pMHC (I-Ab/ova) were used as negative control
and subtracted from experimental sensorgrams. On- and off-
rates were obtained by non-linear curve fitting of subtracted
122 D. Homann et al. / Virology 363 (2007) 113–123curves using the 1:1 Langmuir binding model using the
BIAevaluation program (version 3.0.2).
Statistical analysis
Data handling, analysis and graphic representation were
performed using Prism 4.0a (GraphPad Software, San Diego,
California); p values were calculated by Student's t-test.
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